RSS

eltrombopag

The US FDA has accepted Novartis’ supplemental new drug application (sNDA) and granted priority review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of SAA more

News

The US Food and Drug Association (FDA) expands use of Novartis drug Promacta to include treatment of children ages one and older with chronic immune thrombocytopenia (ITP) more

News